Cancer, Cognitive Function, Compliance, Oral Therapies
Conditions
Keywords
Oral therapies, Cancer, cognitive function, compliance
Brief summary
The investigators propose to evaluate the compliance of oral cancer therapies, particularly the possible link between this observance and cognitive function of patients at initiation of treatment. To our knowledge, this study will be among the first conducted on the issue in France and is an innovative approach in the management of cancer patients. The inclusion of cognitive dysfunction is part of a comprehensive approach to improving the quality of life and fully meets the objectives of both plans cancer, including those of the axis Living during and after cancer highlighted in the Cancer Plan
Interventions
None listed
Sponsors
Centre Francois Baclesse
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age over 18 years, * Patients treated with a first prescription of exclusive oral therapy (chemotherapy and/or targeted therapy) as part of a cancer, * Patients who begin treatment with ZYTIGA ® (abiraterone acetate) are incluables, * Patients with asymptomatic brain metastases are incluables, * Lack of personality disorders and psychiatric illness scalable, * Knowledge of spoken and written French, * Having signed the informed consent of study participation.
Exclusion criteria
* Pathology psychiatric * Refusal to participate, * Patient unable to respond to cognitive tests, - Documented use of drugs, * Heavy drinking, - Cancer primitive central nervous system, - Participation in a clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assess the relationship between cognitive function at baseline oral anti-cancer treatment and adherence to treatment. | 8 months |
Countries
France
Outcome results
None listed